Dulaglutide Versus Liraglutide in Obese Type 2 Diabetic Adolescents Using Metformin

Not Applicable

Completed

• Conditions: Adolescent Obesity; Type 2 Diabetes Treated With Insulin; Obesity
• Interventions: Drug: Liraglutide; Drug: Dulaglutide

• Registration Number: NCT04829903
• Lead Sponsor: Corporacion Parc Tauli

Brief Summary

To compare the efficacy and effect on glycemic control of Dulaglutide versus Liraglutide in obese Type 2 diabetic adolescents using metformin

Detailed Description

To observe the efficacy, effect on glycemic control, impact on BMI and incidence of adverse effects of Dulaglutide and to compare it to Liraglutide in individuals aged thirteen to eighteen who have Type 2 diabetes mellitus and are obese.

Study Timeline

• Study Start: 2020-01-02
• Primary Completion: 2021-03-29
• Study First Submitted: 2021-03-29
• Study First Submitted QC: 2021-04-01
• Study First Posted: 2021-04-02
• Study Completion: 2021-11-20
• Status Verified: 2022-03
• Last Update Submitted: 2022-03-11
• Last Update Posted: 2022-03-14

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 116

Inclusion Criteria

• Type 2 Diabetes Mellitus
• Obese
• Taking metformin
• Male or female

Exclusion Criteria

• Non obese
• Not taking metformin
• Taking other injectable diabetic medications

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Group LIR	Liraglutide	Group taking Liraglutide injections
Group DUL	Dulaglutide	Group taking Dulaglutide injections

Primary Outcome Measures

Name	Time	Method
Adverse effects	24 weeks for the duration of the study	Recording of adverse effects
Glycemic level	24 weeks for the duration of the study	HbA1c
BMI	24 weeks for the duration of the study	BMI measurements using weight and height measurements (anthropometric)

Trial Locations

Locations (1)

Zainab Khan; 🇵🇰 Lahore, Punjab, Pakistan